Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide in pediatric Lennox-Gastaut Syndrome
NCT01405053Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2011
- Primary completion
- Nov 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of rufinamide in Lennox-Gastaut syndrome (LGS) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Child Behavior Checklist Total Problem T-scores at 106 weeks and Change From Baseline in Child Behavior Checklist Total Problem T-Scores at 106 weeks. Started Jun 2011; status: completed.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT01405053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01405053.